New data from Pfizer’s clinical trial of its oral Covid-19 antiviral drug has been made available confirming the treatment’s high level of effectiveness.
Additional data from Pfizer's clinical trial of its oral Covid-19 antiviral drug confirm the treatment's high level of effectiveness, the company says.https://t.co/OEZYlgSBf6
— NBC News (@NBCNews) December 14, 2021
From NBC News:
In the final analysis of its Phase 2/3 clinical trial, the antiviral, called Paxlovid, was found to be 89 percent effective at preventing high-risk people from being hospitalized or dying from Covid, the company said.
The findings are consistent with the results of the interim analysis the company released last month, although the full data have not been made public for scientists to review.
Results for the pill were so encouraging Pfizer applied for emergency use authorization from the FDA during the clinical trials.
Pfizer’s antiviral treatment consists of three pills taken twice daily for five days. Currently, the only approved medications required being administered via IV or injection.
Pfizer also says research indicates that the Paxlovid is effective against the omicron variant of the virus, although additional testing would be needed to confirm.
Lab studies also suggest the drug, called Paxlovid, will remain potent against the omicron variant, which has been rapidly spreading across the globe. https://t.co/fMTHpuqa7J
— USA TODAY (@USATODAY) December 14, 2021